Next-Generation Antibody Discovery and Development Technology

下一代抗体发现和开发技术

基本信息

  • 批准号:
    9174883
  • 负责人:
  • 金额:
    $ 87.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Project Title: Next-Generation Antibody Discovery and Development Technology Organization: GigaGen Inc. PI: David S. Johnson, Ph.D. Despite an enormous investment in novel therapies, cancer still accounts for 25% of US deaths, killing >1500 people every day. For example, only 25% of pancreatic cancer patients and 17% of lung cancer patients survive one year after diagnosis. Additionally, oncology treatments cost $127 billion per year in the US, and are expected to grow at 27% per year through 2020. Monoclonal antibodies (mAbs) are now the biological agents of choice for cancer therapy. Three of the top six grossing therapeutics worldwide (bevacizumab, rituximab, and trastuzumab) are oncology mAbs. Today, most mAb discovery programs use either some flavor of single chain variable fragment (scFv) display or mouse immunization followed by hybridoma isolation. Display technologies like phage display have tremendous ease of use, which enables R&D programs to screen through billions of antibodies in parallel. Unlike conventional phage display technologies, mouse immunizations produce fully natural antibodies, which are often easier to develop than antibodies discovered through display. Though display and mouse immunizations have produced breakthrough therapeutic antibodies, R&D programs are always looking for faster, deeper, and more efficient antibody technologies. The Specific Aim of this IMAT Phase II SBIR project is to develop GigaLink™, a next-generation high-throughput molecular technology for discovery and development of oncology drugs from mammalian B cell repertoires. GigaLink™ is the only technology that uses primary B cells to make millions- to billions-diverse DNA libraries of antibodies, and then expresses the DNA libraries as protein for affinity screening and antigen discovery. As a DNA-based technology, GigaLink™ uniquely enables massively parallel antibody screening, engineering, and development. A successful IMAT Phase II SBIR project will show that the GigaLink™ antibody R&D platform can help our customers understand basic tumor immunology and discover and develop therapeutic antibody candidates. We will use the profits from GigaLink™ service revenues plus venture capital to build our own internal programs for oncology therapeutic antibody discovery.
项目总结 项目名称:新一代抗体发现与开发技术 组织:GigaGen Inc. 派:大卫·S·约翰逊,博士。 尽管在新疗法上投入了大量资金,但癌症仍占美国死亡人数的25%,导致1500人死亡 每天都有人。例如,只有25%的胰腺癌患者和17%的肺癌患者 确诊后存活一年。此外,在美国,肿瘤治疗每年花费1270亿美元,而且 预计到2020年将以每年27%的速度增长。 目前,单抗是治疗癌症的首选生物制剂。前六名中的三名 全世界最畅销的治疗药物(贝伐单抗、利妥昔单抗和曲妥珠单抗)都是肿瘤学单抗。今天,大多数 MAb发现程序使用某种风格的单链可变片段(ScFv)显示或鼠标 免疫后进行杂交瘤分离。像噬菌体展示这样的展示技术非常容易 这使得研发程序能够并行地通过数十亿种抗体进行筛选。与传统不同 噬菌体展示技术,小鼠免疫产生完全自然的抗体,通常更容易 发展出比通过展示发现的抗体更好的抗体。 尽管展示和老鼠免疫已经产生了突破性的治疗性抗体,但研发计划 一直在寻找更快、更深、更有效的抗体技术。这次IMAT的具体目的是 第二阶段SBIR项目是开发GigaLink™,这是一种新一代高通量分子技术,用于 哺乳动物B细胞库中肿瘤药物的发现和发展。GigaLink™是唯一 使用原代B细胞制造数百万到数十亿种不同的DNA抗体库的技术,然后 将DNA文库表达为蛋白质,用于亲和筛选和抗原发现。作为一种基于DNA的 技术,GigaLink™独一无二地实现了大规模并行抗体筛选、工程和 发展。 一个成功的IMAT第二期SBIR项目将表明GigaLink™抗体研发平台可以帮助我们的 客户了解基本的肿瘤免疫学,并发现和开发治疗性抗体候选。 我们将使用GigaLink™服务收入的利润加上风险资本来建立我们自己的内部 肿瘤学治疗性抗体发现计划。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Scott Johnson其他文献

David Scott Johnson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Scott Johnson', 18)}}的其他基金

Commercialization of an Advanced Technology for T Cell Receptor Analysis and Engineering
T 细胞受体分析和工程先进技术的商业化
  • 批准号:
    9193662
  • 财政年份:
    2016
  • 资助金额:
    $ 87.98万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9139000
  • 财政年份:
    2016
  • 资助金额:
    $ 87.98万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9304957
  • 财政年份:
    2016
  • 资助金额:
    $ 87.98万
  • 项目类别:
Production Technology for Recombinant Intravenous Immunoglobulin
重组静脉免疫球蛋白生产技术
  • 批准号:
    8976337
  • 财政年份:
    2015
  • 资助金额:
    $ 87.98万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease
用于治疗肺炎球菌疾病的重组超免疫丙种球蛋白
  • 批准号:
    8979450
  • 财政年份:
    2015
  • 资助金额:
    $ 87.98万
  • 项目类别:
Therapeutic Antibody Discovery from Pancreatic Cancer B Cell Repertoires
从胰腺癌 B 细胞库中发现治疗性抗体
  • 批准号:
    8832750
  • 财政年份:
    2014
  • 资助金额:
    $ 87.98万
  • 项目类别:
B Cell Repertoire Molecular Platform for Antibody Drug Discovery
用于抗体药物发现的 B 细胞库分子平台
  • 批准号:
    8756836
  • 财政年份:
    2014
  • 资助金额:
    $ 87.98万
  • 项目类别:
Cloud-Based Bioinformatics for Immune Repertoire Analysis
用于免疫谱分析的基于云的生物信息学
  • 批准号:
    8642691
  • 财政年份:
    2012
  • 资助金额:
    $ 87.98万
  • 项目类别:
Massively Parallel Haplotyping
大规模平行单倍型分析
  • 批准号:
    8198444
  • 财政年份:
    2012
  • 资助金额:
    $ 87.98万
  • 项目类别:
Molecular Kits and Software for Lymphoid Malignancy Work-ups
用于淋巴恶性肿瘤检查的分子试剂盒和软件
  • 批准号:
    8647029
  • 财政年份:
    2012
  • 资助金额:
    $ 87.98万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 87.98万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了